Special Methodological Issues in Pharmacoepidemiology Studies of Vaccine Safety

Pharmacoepidemiology, Fourth Edition

Volumn , Issue , 2007, Pages 455-485

  Chen, Robert T ^a   Davis, Robert L ^b   Rhodes, Philip H ^a  

^a CENTERS FOR DIS CONTR AND PREV   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Analyses, confounding, and bias; Assessment of causality; Computerized immunization registries; Data and Safety Monitoring Boards (DSMBs); DNA vaccine and new adjuvant exploration; Spontaneous reporting systems (SRS); Vaccine adverse events (AEs); Vaccine safety methodological issues; Vaccine safety monitoring

Indexed keywords

EID: 34548386334     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470059876.ch30     Document Type: Chapter

References (310)

1. World Bank. World Development Report 1993: Investing in Health. New York: Oxford University Press, 1993.
2. England S, Loevinsohn B, Melgaard B, Kou U, Jha P. The Evidence Base for Interventions to Reduce Mortality from Vaccine-Preventable Diseases in Low and Middle-Income Countries. World Health Organization Commission on Macroeconomics and Health, working paper series, paper no. WG5, 10. Geneva: WHO, 2001.
3. Centers for Disease Control and Prevention. Achievements in public health, 1900-1999: impact of vaccines universally recommended for children-United States, 1990-1998. MMWR Morb Mortal Wkly Rep 1999; 48: 243-8.
4. Wilson GS. The Hazards of Immunization. London: Athlone Press, 1967.
5. Chen RT. Vaccine risks: real, perceived and unknown. Vaccine 1999; 17(suppl 3): S41-6.
6. Plotkin SA. Lessons learned concerning vaccine safety. Vaccine 2001; 20(suppl 1): S16-19.
7. Freed GL, Clark SJ, Hibbs BF, Santoli JM. Parental vaccine safety concerns. The experiences of pediatricians and family physicians. Am J Prev Med 2004; 26: 11-14.
8. Duclos P, Delo A, Aguado T, Bilous J, Birmingham M, Kieny MP et al. Immunization safety priority project at the World Health Organization. Semin Pediatr Infect Dis 2003; 14: 233-9.
9. Gangarosa EJ, Galazka AM, Wolfe CR, Phillips LM, Gangarosa RE, Miller E et al. Impact of anti-vaccine movements on pertussis control: the untold story. Lancet 1998; 351: 356-61.
10. Orenstein WA. DTP vaccine litigation, 1988. Am J Dis Child 1990; 144: 517.
11. Institute of Medicine. Liability for the production and sale of vaccine. In: Sanford JP, ed., Vaccine Supply and Innovation. Washington, DC: National Academy Press, 1985; pp. 85-122.
12. Ball LK, Ball R, Pratt RD. An assessment of thimerosal use in childhood vaccines. Pediatrics 2001; 107: 1147-54.
13. Verstraeten T, Davis RL, DeStefano F, Lieu TA, Rhodes PH, Black SB et al. Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases. Pediatrics 2003; 112: 1039-48.
14. Joellenbeck LM, Zwanziger LL, Durch JS, Strom BL, eds., Committee to Assess the Safety and Efficacy of the Anthrax Vaccine. The Anthrax Vaccine: Is it safe? Does it work? Washington, DC: National Academy Press, 2002.
15. Chen RT, Lane JM. Myocarditis: the unexpected return of smallpox vaccine adverse events. Lancet 2003; 362: 1345-6.
16. Halsell JS, Riddle JR, Atwood JE, Gardner P, Shope R, Poland GA et al. Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel. JAMA 2003; 289: 3283-9.
17. Spooner MH. Measles outbreak in UK linked to fears about MMR vaccine. CMAJ 2002; 166: 1075.
18. Balinska MA. L'affaire hepatite B en France. Espirit 2001; 276: 34-48.
19. Howson CP, Howe CJ, Fineberg HV, eds, Adverse Effects of Pertussis and Rubella Vaccines: A Report of the Committee to Review the Adverse Consequences of Pertussis and Rubella Vaccines. Washington, DC: National Academy Press, 1991.
20. Stratton KR, Howe CJ, Johnston RB, eds, Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Causality. Washington, DC: National Academy Press, 1994.
21. Miller E, Waight P, Farrington P. Safety assessment postlicensure. Dev Biol Stand 1998; 95: 235-43.
22. Johnston RB Jr. Do vaccines cause harm? The need for open-minded analysis based on science and reason. Adv Pediatr 2003; 50: 231-44.
23. Stratton K, Gable A, McCormick M, eds, Immunization Safety Review Committee. Immunization Safety Review: Thimerosal-Containing Vaccines and Neurodevelopmental Disorders. Washington, DC: National Academy Press, 2001.
24. Stratton K, Gable A, Shetty PMM, eds, Immunization Safety Review Committee. Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism. Washington, DC: National Academy Press, 2001.
25. Stratton K, Wilson CB, McCormick M, eds, Immunization Safety Review Committee. Immunization Safety Review: Multiple Immunizations and Immune Dysfunction. Washington, DC: National Academy Press; 2002.
26. Stratton K, McCormick M, eds, Immunization Safety Review Committee. Immunization Safety Review: SV40 Contamination of Polio Vaccine and Cancer. Washington, DC: National Academy Press, 2002.
27. Stratton K, Almario D, McCormick M, eds, Immunization Safety Review Committee. Immunization Safety Review: Hepatitis B Vaccine and Demyelinating Neurological Disorders. Washington, DC: National Academy Press, 2002.
28. Stratton K, Almario DA, Wizeman TM, McCormick MC, eds, Immunization Safety Review Committee. Immunization Safety Review: Vaccinations and Sudden Unexpected Death in Infancy. Washington, DC: National Academy Press, 2003.
29. Stratton K, Almario DA, Wizeman TM, McCormick MC, eds, Immunization Safety Review Committee. Immunization Safety Review: Influenza Vaccines and Neurological Complications. Washington, DC: National Academy Press, 2003.
30. Baylor NW, Midthun K. Regulation and testing of vaccines. In: Plotkin S, Orenstein WA, eds, Vaccines, 4th edn. Philadelphia, PA: W.B. Saunders, 2003; pp. 1539-81.
31. Ellis RW. Technologies for making new vaccines. In: Plotkin S, Orenstein WA, eds, Vaccines, 4th edn. Philadelphia, PA: W.B. Saunders, 2003; pp. 1177-97.
32. Offit PA, Jew RK. Addressing parents' concerns: do vaccines contain harmful preservatives, adjuvants, additives, or residuals? Pediatrics 2003; 112: 1394-7.
33. Hutin YJ, Hauri AM, Armstrong GL. Use of injections in healthcare settings worldwide, 2000: literature review and regional estimates. BMJ 2003; 327: 1075.
34. Dziekan G, Chisholm D, Johns B, Rovira J, Hutin YJ. The cost-effectiveness of policies for the safe and appropriate use of injection in healthcare settings. Bull World Health Organ 2003; 81: 277-85.
35. Miller D, Wadsworth J, Diamond J, Ross E. Pertussis vaccine and whooping cough as risk factors in acute neurologic illness and deaths in young children. Dev Biol Stand 1985; 61: 389-94.
36. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, Keenlyside RA, Ziegler DW, Retailliau HF et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol 1979; 110: 105-23.
37. Centers for Disease Control and Prevention. Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1997; 46: 1-25.
38. McGoldrick MD, Bailie GR. Nonnarcotic analgesics: prevalence and estimated economic impact of toxicities. Ann Pharmacother 1997; 31: 221-7.
39. Marcuse EK, Wentz KR. The NCES reconsidered: summary of a 1989 workshop. National Childhood Encephalopathy Study. Vaccine 1990; 8: 531-5.
40. Alderslade R, Bellman MH, Rawson NSB, Ross EM, Miller DL. The National Childhood Encephalopathy Study. In: Whooping Cough: Reports from the Committee on the Safety of Medicines and the Joint Committee on Vaccination and Immunisation. Department of Health and Social Security. London: HM Stationery Office, 1981; pp. 79-169.
41. Wentz KR, Marcuse EK. Diphtheria-tetanus-pertussis vaccine and serious neurologic illness: an updated review of the epidemiologic evidence. Pediatrics 1991; 87: 287-97.
42. Neustadt RE, Fineberg HV. The Swine Flu Affair: Decision-Making on a Slippery Disease. Washington, DC: US Government Printing Office, 1978.
43. Kurland LT, Wiederholt WC, Kirkpatrick JW, Potter HG, Armstrong P. Swine influenza vaccine and Guillain-Barre syndrome. Epidemic or artifact? Arch Neurol 1985; 42: 1089-90.
44. Langmuir AD, Bregman DJ, Kurland LT, Nathanson N, Victor M. An epidemiologic and clinical evaluation of Guillain-Barre syndrome reported in association with the administration of swine influenza vaccines. Am J Epidemiol 1984; 119: 841-79.
45. Safranek TJ, Lawrence DN, Kurland LT, Culver DH, Wiederholt WC, Hayner NS et al. Reassessment of the association between Guillain-Barre syndrome and receipt of swine influenza vaccine in 1976-1977: results of a two-state study. Expert Neurology Group. Am J Epidemiol 1991; 133: 940-951.
46. Murphy TV, Gargiullo PM, Massoudi MS, Nelson DB, Jumaan AO, Okoro CA et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001; 344: 564-72.
47. Kramarz P, France EK, DeStefano F, Black SB, Shinefield H, Ward JI et al. Population-based study of rotavirus vaccination and intussusception. Pediatr Infect Dis J 2001; 20: 410-16.
48. Simonsen L, Morens D, Elixhauser A, Gerber M, Van Raden M, Blackwelder W. Effect of rotavirus vaccination programme on trends in admission of infants to hospital for intussusception. Lancet 2001; 358: 1224-9.
49. Hall AJ. Ecological studies and debate on rotavirus vaccine and intussusception. Lancet 2001; 358: 1197-8.
50. Murphy TV, Gargiullo PM, Wharton M. More on rotavirus vaccination and intussusception. N Engl J Med 2002; 346: 211-12.
51. Schumacher W. Legal/ethical aspects of vaccinations. Dev Biol Stand 1979; 43: 435-8.
52. Fine PE. Herd immunity: history, theory, practice. Epidemiol Rev 1993; 15: 265-302.
53. Hardin G. The tragedy of the commons. Science 1968; 162: 1243-8.
54. Fine PE, Clarkson JA. Individual versus public priorities in the determination of optimal vaccination policies. Am J Epidemiol 1986; 124: 1012-20.
55. Nathanson N, Langmuir AD. The Cutter incident. Poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United States during the spring of 1955. I. Background. Am J Hyg 1963; 78: 16-18.
56. Shah KV. Simian virus 40 and human disease. J Infect Dis 2004; 190: 2061-4.
57. Food and Drug Administration. Bovine-derived materials: Agency letters to manufacturers of FDA-regulated products. Fed Reg 1994; 59: 44591-4.
58. Milstien J, Dellepiane N, Lamert S, Belgharbi L, Rolls C, Knezevic I et al. Vaccine quality-can a single standard be defined? Vaccine 2002; 20: 1000-3.
59. Centers for Disease Control and Prevention. Poliomyelitis prevention in the United States: updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2000; 49: 1-25.
60. Anonymous. Two MMR vaccines withdrawn. Lancet 1992; 340: 922.
61. Schmitt HJ, Just M, Neiss A. Withdrawal of a mumps vaccine: reasons and impacts. Eur J Pediatr 1993; 152: 387-8.
62. Kimura M, Kuno-Sakai H, Yamazaki S, Yamada A, Hishiyama M, Kamiya H et al. Adverse events associated with MMR vaccines in Japan. Acta Paediatr Jpn 1996; 38: 205-11.
63. Lathrop SL, Ball R, Haber P, Mootrey GT, Braun MM, Shadomy SV etal. Adverse event reports following vaccination for Lyme disease: December 1998-July 2000. Vaccine 2002; 20: 1603-8.
64. Singleton JA, Lloyd JC, Mootrey GT, Salive ME, Chen RT. An overview of the vaccine adverse event reporting system (VAERS) as a surveillance system. Vaccine 1999; 17: 2908-10.
65. Evans G. Vaccine injury compensation programs worldwide. Vaccine 1999; 17(suppl 3): S25-35.
66. Evans G. Vaccine liability and safety: a progress report. Pediatr Infect Dis J 1996; 15: 477-8.
67. Evans G, Harris D, Levine EM. Legal issues. In: Plotkin S, Orenstein WA, eds, Vaccines, 4th edn. Philadelphia, PA: W.B. Saunders, 2003; pp. 1591-617.
68. Centers for Disease Control and Prevention. Public Health Service recommendations on smallpox vaccination. MMWR Morb Mortal Wkly Rep 1971; 20: 339-45.
69. Bottiger M. The elimination of polio in the Scandinavian countries. Public Health Rev 1993; 21: 27-33.
70. Henderson DA. Countering the posteradication threat of smallpox and polio. Clin Infect Dis 2002; 34: 79-83.
71. Farrington P, Pugh S, Colville A, Flower A, Nash J, Morgan-Capner P et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet 1995; 345: 567-9.
72. Dourado I, Cunha S, Teixeira MG, Farrington CP, Melo A, Lucena R et al. Outbreak of aseptic meningitis associated with mass vaccination with a urabe-containing measles-mumps-rubella vaccine: implications for immunization programs. Am J Epidemiol 2000; 151: 524-30.
73. Ki M, Park T, Yi SG, Oh JK, Choi B. Risk analysis of aseptic meningitis after measles-mumps-rubella vaccination in Korean children by using a case-crossover design. Am J Epidemiol 2003; 157: 158-65.
74. Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T etal. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 2004; 350: 896-903.
75. Stetler HC, Orenstein WA, Bart KJ, Brink EW, Brennan JP, Hinman AR. History of convulsions and use of pertussis vaccine. J Pediatr 1985; 107: 175-9.
76. Robbins JB, Pittman M, Trollfors B, Lagergard TA, Taranger J, Schneerson R. Primum non nocere: a pharmacologically inert pertussis toxoid alone should be the next pertussis vaccine. Pediatr Infect Dis J 1993; 12: 795-807.
77. Brown EG, Dimock K, Wright KE. The Urabe AM9 mumps vaccine is a mixture of viruses differing at amino acid 335 of the hemagglutinin-neuraminidase gene with one form associated with disease. J Infect Dis 1996; 174: 619-22.
78. Kew OM, Nottay BK. Molecular epidemiology of polioviruses. Rev Infect Dis 1984; 6(suppl 2): S499-S504.
79. Plotkin SA, Rupprecht CE, Koprowski H. Rabies vaccine. In: Plotkin SA, Mortimer EA, eds, Vaccines, 4th edn. Philadelphia: W.B. Saunders, 2003; pp. 1011-38.
80. Mathieu M. Biologics Development: A Regulatory Overview, 4th edn. Waltham, MA: Parexel, 2004.
81. Decker MD, Edwards KM, Steinhoff MC, Rennels MB, Pichichero ME, England JA et al. Comparison of 13 acellular pertussis vaccines adverse reactions. Pediatrics 1995; 96: 557-66.
82. Rosenthal KL, McVittie LD. The clinical testing of preventive vaccines. In: Mathieu M, ed., Biologics Development: A Regulatory Overview. Waltham, MA: Parexel, 1993; pp. 119-30.
83. Pinichiero ME. Acellular pertussis vaccine: towards an improved safety profile. Drug Experience 1996; 15: 311-24.
84. Francis T, Korns R, Voight R. An evaluation of the 1954 poliomyelitis vaccine trials: summary report. Am J Public Health 1955; 45: 1-63.
85. Eskola J, Kayhty H, Takala A. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. N Engl J Med 1990; 323: 1381-7.
86. Black SB, Shinefield HR, Lampert D, Fireman B, Hiatt RA, Polen M et al. Safety and immunogenicity of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in infancy. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group. Pediatr Infect Dis J 1991; 10: 92-6.
87. Chen RT. Safety of acellular pertussis vaccine: follow-up studies. Dev Biol Stand 1997; 89: 373-5.
88. Bonhoeffer J, Kohl K, Chen R, Duclos P, Heijbel H, Heininger U et al. The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine 2002; 21: 298-302.
89. Heijbel H, Ciofidegli Atti MC, Harzer E, Liese J, Preziosi MP, Rasmussen F et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Dev Biol Stand 1997; 89: 101-3.
90. Fine PE, Chen RT. Confounding in studies of adverse reactions to vaccines. Am J Epidemiol 1992; 136: 121-35.
91. Aaby P, Jensen H, Samb B, Cisse B, Sodemann M, Jakobsen M et al. Differences in female-male mortality after high-titre measles vaccine and association with subsequent vaccination with diphtheria-tetanus-pertussis and inactivated poliovirus: reanalysis of West African studies. Lancet 2003; 361: 2183-8.
92. Hall AJ, Cutts FT. Lessons from measles vaccination in developing countries. BMJ 1993; 307: 1294-5.
93. Cutts FT, Fine PE. Caution-mortality ratios ahead. Lancet 2003; 361: 2169-70.
94. Zanoni G, DNTG. Fourth Report on the Green Channel Activities and the Monitoring System of Reactions to Vaccines in the Veneto Region: Analysis of the Three Year Period 1997-1999, General Summary 1992-99. University of Verona, Immunology Section, 2000.
95. Goodwin H, Nash M, Gold M, Heath TC, Burgess MA. Vaccination of children following a previous hypotonic-hyporesponsive episode. J Paediatr Child Health 1999; 35: 549-52.
96. Gold MS. Hypotonic-hyporesponsive episodes following pertussis vaccination: a cause for concern? Drug Saf 2002; 25: 85-90.
97. Baraff LJ, Cody CL, Cherry JD. DTP-associated reactions: an analysis by injection site, manufacturer, prior reactions, and dose. Pediatrics 1984; 73: 31-6.
98. Baraff LJ, Manclark CR, Cherry JD, Christenson P, Marcy SM. Analyses of adverse reactions to diphtheria and tetanus toxoids and pertussis vaccine by vaccine lot, endotoxin content, pertussis vaccine potency and percentage of mouse weight gain. Pediatr Infect Dis J 1989; 8: 502-7.
99. Centers for Disease Control and Prevention. Notice to readers: manufacturer's recall of human rabies vaccine-April 2, 2004. MMWR Recomm Rep 2004; 53: 1-2.
100. Chen RT, Pool V, Takahashi H, Weniger BG, Patel B. Combination vaccines: postlicensure safety evaluation. Clin Infect Dis 2001; 33(suppl 4): S327-33.
101. Wise RP, Kiminyo KP, Salive ME. Hair loss after routine immunizations. JAMA 1997; 278: 1176-8.
102. Centers for Disease Control and Prevention. Intussusception among recipients of rotavirus vaccine-United States, 1998-1999. MMWR Morb Mortal Wkly Rep 1999; 48: 577-81.
103. Chen RT. Surveillance for vaccine adverse events and public health disease: similarities and differences. Pharmacoepidemiol Drug Saf 1996; 5: S45.
104. Division of Immunization. Vaccine-associated adverse events in Canada, 1992 Report. Can Commun Dis Rep 1995; 21: 117-28.
105. Chen RT, Rastogi SC, Mullen JR, Hayes SW, Cochi SL, Donlon JA et al. The Vaccine Adverse Event Reporting System (VAERS). Vaccine 1994; 12: 542-50.
106. Miller E, Goldacre M, Pugh S, Colville A, Farrington P, Flower A et al. Risk of aseptic meningitis after measles, mumps, and rubella vaccine in UK children. Lancet 1993; 341: 979-82.
107. CDC. Vaccine Identification Standards Initiative. Available at: http://www.edc.gov/nip/visi/default.htm.
108. Halsey NA. An update on pediatric immunization. Adv Pediatr Infect Dis 1995; 10: 187-225.
109. Chen RT, Kent JH, Rhodes PH, Simon P, Schonberger LS. Investigation of a possible association between influenza vaccination and Guillain-Barre syndrome in the United States, 1990-1991. Post Marketing Surveillance 1992; 6: 5-6.
110. Lasky T, Terracciano GJ, Magder L, Koski CL, Ballesteros M, Nash D et al. The Guillain-Barre syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med 1998; 339: 1797-1802.
111. Miller D, Wadsworth J, Diamond J, Ross E. Pertussis vaccine and whooping cough as risk factors in acute neurological illness and death in young children. Dev Biol Stand 1985; 61: 389-94.
112. Laboratory Centre for Disease Control. Report of the working group on the possible relationship between hepatitis B vaccination and the chronic fatigue syndrome. Can Med Assoc J 1993; 149: 314-19.
113. Bernier RH, Frank JA Jr, Dondero TJ Jr, Turner P. Diphtheria-tetanus toxoids-pertussis vaccination and sudden infant deaths in Tennessee. J Pediatr 1982; 101: 419-21.
114. Wakefield AJ, Murch SH, Anthony A, Linnell J, Casson DM, Malik M et al. Ileal-lymphoid-nodular hyperplasia, nonspecific colitis, and pervasive developmental disorder in children. Lancet 1998; 351: 637-41.
115. Thompson NP, Montgomery SM, Pounder RE, Wakefield AJ. Is measles vaccination a risk factor for inflammatory bowel disease? Lancet 1995; 345: 1071-4.
116. Expanded Programme on Immunization. Lack of evidence that hepatitis B vaccine causes multiple sclerosis. Wkly Epidemiol Rec 1997; 72: 149-56.
117. Mortimer EA, Jones P, Adelson L. DTP and SIDS [letter]. Pediatr Infect Dis 1983; 2: 492-3.
118. Goodson BD. How will we know if thimerosal leads to neurodevelopmental problems? 38th National Immunization Conference, Nashville, TN, May 14, 2004.
119. Ray WA, Griffin MR. Re: "Confounding in studies of adverse reactions to vaccines". Am J Epidemiol 1994; 139: 229-30.
120. Ellenberg SS. Safety considerations for new vaccine development. Pharmacoepidemiol Drug Saf 2001; 10: 411-15.
121. Lesko SM, Mitchell AA. The safety of acetaminophen and ibuprofen among children younger than two years old. Pediatrics 1999; 104: e39.
122. Glass RI, Bresee JS, Parashar UD, Jiang B, Gentsch J. The future of rotavirus vaccines: a major setback leads to new opportunities. Lancet 2004; 363: 1547-50.
123. Cooper WO, Boyce TG, Wright PF, Griffin MR. Do childhood vaccines have non-specific effects on mortality? Bull World Health Organ 2003; 81: 821-6.
124. Scott TF, Bonanno DE. Reactions to live-measles-virus vaccine in children previously inoculated with killed-virus vaccine. N Engl J Med 1967; 277: 248-50.
125. Kristensen I, Aaby P, Jensen H. Routine vaccinations and child survival: follow up study in Guinea-Bissau, West Africa. BMJ 2000; 321: 1435-8.
126. Bennett JV, Cutts FT, Katz SL. Edmonston-Zagreb measles vaccine: a good vaccine with an image problem. Pediatrics 1999; 104: 1123-4.
127. Rennels MB. The rotavirus vaccine story: a clinical investigator's view. Pediatrics 2000; 106: 123-5.
128. Rastogi SC, ed., International Workshop: Harmonization of Reporting of Adverse Events Following Vaccination. Rockville, MD: Food and Drug Administraion/CBER, 1993.
129. Wilholm B-E, Olsoon S, Moore N, Wood S. Spontaneous reporting systems outside the US. In: Strom BL, ed., Pharmacoepidemiology, 2nd edn. Chichester: John Wiley & Sons, 1994; pp. 139-55.
130. Jonville-Bera AP, Autret E, Galy-Eyraud C, Hessel L. Thrombocytopenic purpura after measles, mumps and rubella vaccination: a retrospective survey by the French regional pharmacovigilance centres and Pasteur-Merieux Serums et Vaccins. Pediatr Infect Dis J 1996; 15: 44-8.
131. Takahashi H. Need for improved vaccine safety surveillance. Vaccine 2000; 19: 1004.
132. Mansoor O, Pillans PI. Vaccine adverse events reported in New Zealand 1990-5. N Z Med J 1997; 110: 270-2.
133. Taranger J, Holmberg K. Urgent to introduce countrywide and systematic evaluation of vaccine side effects. Lakartidningen 1992; 89: 1691-3.
134. da Silveira CM, Salisbury DM, de Quadros CA. Measles vaccination and Guillain-Barre syndrome. Lancet 1997; 349: 14-16.
135. Duclos P. Surveillance of secondary effects of vaccination. Sante 1994; 4: 215-20.
136. Galindo Santana BM, Galindo Sardina MA, Perez RA. Adverse reaction surveillance system for vaccination in the Republic of Cuba. Rev Cubana Med Trop 1999; 51: 194-200.
137. Andersen MM, Ronne T. Side-effects with Japanese encephalitis vaccine. Lancet 1991; 337: 1044.
138. Sokhey J. Adverse events following immunization: 1990. Indian Pediatr 1991; 28: 593-607.
139. Squarcione S, Vellucci L. Adverse reactions following immunization in Italy in the years 1991-93. Ig Mod 1996; 105: 1419-31.
140. Fescharek R, Arras-Reiter C, Arens ER, Quast U, Maass G. [Oral vaccines against poliomyelitis and vaccination-related paralytic poliomyelitis in Germany. Do we need a new immunization strategy?] Wien Med 1997; 147: 456-61 (in German).
141. Vermeer-de Bondt PE, Wesselo C, Dzaferagic A, Phaff TAJ. Adverse Events Following Immunisation under the National Vaccination Programme of the Netherlands. Part VIII: Reports in 2001. Bilthoven: RIVM, 2003.
142. Brito GS. System of Investigation and Notification of Adverse Events Following Imunization, preliminary report. Sao Paolo, Brazil: Health Department, 1991.
143. Sokhey J, Sarkars. Vaccines: quality issues. J Indian Med Assoc 2000; 98: 22-3.
144. Duclos P, Hockin J, Pless R, Lawlor B. Reporting vaccineassociated adverse events. Can Fam Physician 1997; 43: 1551-6.
145. Centers for Disease Control. National Childhood Vaccine Injury Act. Requirements for permanent vaccination records and for reporting of selected events after vaccination. MMWR Morb Mortal Wkly Report 1988; 37: 197-200.
146. Haber P, Rashidee A, Zhou W, English R. Web-based Reporting: 10 months experience in the VAERS. Pharmacoepidemiol Drug Saf 2003; 12: S1-S189.
147. Centers for Disease Control and Prevention. Smallpox vaccine adverse events monitoring and response system for the first stage of the smallpox vaccination program. MMWR Morb Mort Wkly Rep 2003; 52: 88-9, 99.
148. Rashidee AH, Chen RT, Lugg M, Black S. Integrating vaccine safety initiatives in immunization registry/systems. Pharmacoepidemiol Drug Saf 2002; 11: (suppl 1), S195.
149. Zanardi LR, Haber P, Mootrey GT, Niu MT, Wharton M. Intussusception among recipients of rotavirus vaccine: reports to the vaccine adverse event reporting system. Pediatrics 2001; 107: E97.
150. Centers for Disease Control and Prevention. Adverse events associated with 17D-derived yellow fever vaccination United States 2001-2002. CDC Morb Mort Wkly Rep 2002; pp. 989-93.
151. Centers for Disease Control and Prevention. Cardiac adverse events following smallpox vaccination-United States, 2003. MMWR Morb Mort Wkly Rep 2003; 52: 248-50.
152. Centers for Disease Control and Prevention. Surveillance for adverse events associated with anthrax vaccination-U.S. Department of Defense, 1998-2000. MMWR Morb Mort Wkly Rep 2000; 49: 341-5.
153. Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)-United States, 1991-2001. MMWR Surveill Summ 2003; 52: 1-24.
154. Food and Drug Administration. COSTART-Coding Symbols for Thesaurus of Adverse Reaction Terms, 3rd edn. Rockville, MD: FDA, 1989.
155. Brown EG, Wood L, Wood S. The Medical Dictionary for Regulatory Activities (MedDRA). Drug Saf 1999; 20: 109-17.
156. Scheifele D, Duval B, De Serres G, Skowronski DM. Unique roles of a data and safety monitoring board in vaccine safety trials with compressed timelines and urgent implications. Control Clin Trials 2003; 24: 99-104.
157. Collet JP, MacDonald N, Cashman N, Pless R. Monitoring signals for vaccine safety: the assessment of individual adverse event reports by an expert advisory committee. Advisory Committee on Causality Assessment. Bull World Health Organ 2000; 78: 178-85.
158. 1996 Immunisation Against Infectious Disease. London: HMSO, 1996.
159. Lindquist M, Edwards IR. The WHO Programme for International Drug Monitoring, its database, and the technical support of the Uppsala Monitoring Center. J Rheumatol 2001; 28: 1180-7.
160. World Health Organization. Surveillance of Adverse Events Following Immunization, WHO/EPI/TRAM/93.02 Rev. 1. Geneva: WHO, 1997.
161. World Health Organization. Vaccine supply and quality: surveillance of adverse events following immunization. Weekly Epidemiology Rec 1996; 71: 237-42.
162. Fenichel GM, Lane DA, Livengood JR, Horwitz SJ, Menkes JH, Schwartz JF. Adverse events following immunization: assessing probability of causation. Pediatr Neurol 1989; 5: 287-90.
163. Wassilak SGF, Sokhey J. Monitoring of Adverse Events Following Immunization in the Expanded Programme on Immunization. 91.2, 1-29. Geneva: World Health Organization/EPI/GEN, 1991.
164. Goodman M, Lamm SH, Bellman MH. Temporal relationship modeling: DTP or DT immunizations and infantile spasms. Vaccine 1998; 16: 225-31.
165. Health Council of the Netherlands. Committee on Adverse Reactions to Vaccinations. Adverse Reactions to Vaccines in the National Immunization Programme in 1993, publication no. 1995/08E. The Hague: Health Council of the Netherlands, 1995.
166. Simonsen L, Kane A, Lloyd J, Zaffran M, Kane M. Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. Bull World Health Organ 1999; 77: 789-800.
167. Nathanson N, Langmuir AD. The Cutter incident. Poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United States during the spring of 1955. II. Relationship of poliomyelitis to Cutter vaccine. 1963. Am J Epidemiol 1995; 142: 109-40.
168. Proceedings of a Workshop on the Standardization of Definitions for Post-Marketing Surveillance of Adverse Vaccine Reactions, Ottawa, Canada, October 30-31, 1991. Ottawa, Canada: Laboratory Centre for Disease Control, 1992.
169. Braun MM, Terracciano G, Salive ME, Blumberg DA, Vermeer-de Bondt PE, Heijbel H et al. Report of a US public health service workshop on hypotonic-hyporesponsive episode (HHE) after pertussis immunization. Pediatrics 1998; 102: E52.
170. Ball R, Halsey N, Braun MM. Development of case definitions for acute encephalopathy, encephalitis, and multiple sclerosis reports to the Vaccine Adverse Reporting System. J Clin Epidemiol 2002; 55: 821-30.
171. Food and Drug Administration. International Conference on Harmonisation: Guideline on clinical safety data management: Periodic safety update reports for marketed drugs. Fed Reg 1997; 62: 27470-6.
172. Kohl K, Bonhoeffer J, Chen R. The Brighton Collaboration: enhancing comparability of vaccine safety data. Pharmacoepidemiol Drug Saf 2003; 12: 335-40.
173. Chen RT. Evaluation of vaccine safety after the events of 11 September 2001: role of cohort and case-control studies. Vaccine 2004; 22: 2047-53.
174. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 2001; 286: 2270-9.
175. Sim I, Sanders GD, McDonald KM. Evidence-based practice for mere mortals: the role of informatics and health services research. J Gen Intern Med 2002; 17: 302-8.
176. Rennels MB. Extensive swelling reactions occurring after booster doses of diphtheria-tetanus-acellular pertussis vaccines. Semin Pediatr Infect Dis 2003; 14: 196-198.
177. Kramer MS, Lane DA. Causal propositions in clinical research and practice. J Clin Epidemiol 1992; 45: 639-49.
178. Hill AB. The environment and disease: association or causation. Proc Roy Soc Med 1965; 58: 295-300.
179. Kramer MS. Difficulties in assessing the adverse effects of drugs. Br J Clin Pharmacol 1981; 11: 105-10.
180. Jones JK. Determining causation from case reports. In: Strom BL, ed., Pharmacoepidemiology, 3rd edn. Chichester: John Wiley & Sons, 2000; pp. 525-38.
181. Edsall G, Elliott MW, Peebles TC, Eldred MC. Excessive use of tetanus toxoid boosters. JAMA 1967; 202: 111-13.
182. Henderson DA, Witte JJ, Morris L et al. Paralytic disease associated with oral polio vaccines. JAMA 1964; 190: 153-60.
183. Centers for Disease Control and Prevention. Rubella vaccination during pregnancy-United States, 1971-1988. MMWR Morb Mort Wkly Rep 1989; 38: 289-93.
184. Chen RT, Glasser JW, Rhodes PH, Davis RL, Barlow WE, Thompson RS et al. Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team. Pediatrics 1997; 99: 765-73.
185. Cherry JD. Pertussis and the vaccine controversy. In: Roote RK, Griffiss JM, Warren KS et al., eds, Immunization. New York: Churchill Livingstone, 1989; pp. 47-63.
186. Lane DA. A probabilist's view of causality assessment. Drug Inform J 1984; 18: 323-30.
187. Venuiet J, Berneker G-C, Ciucci AG. Assessing Causes of Adverse Drug Reactions with Special Reference to Standardized Methods. London: Academic Press, 1982.
188. Lane DA, Kramer MS, Hutchinson TA et al. The causality assessment of adverse drug reactions using a Bayesian approach. Pharmaceut Med 1987; 2: 265-83.
189. Finney DJ. The detection of adverse reactions to therapeutic drugs. Stat Med 1982; 1: 153-61.
190. Retailliau HF, Curtis AC, Storr G, Caesar G, Eddins DL, Hattwick MA. Illness after influenza vaccination reported through a nationwide surveillance system, 1976-1977. Am J Epidemiol 1980; 111: 270-8.
191. Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A etal. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 1998; 54: 315-21.
192. Wallenstein S, Gould MS, Kleinman M. Use of the scan statistic to detect time-space clustering. Am J Epidemiol 1989; 130: 1057-64.
193. Martin M, Tsai TF, Cropp B, Chang GJ, Holmes DA, Tseng J et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 2001; 358: 98-104.
194. Martin M, Weld LH, Tsai TF, Mootrey GT, Chen RT, Niu M etal. Advanced age a risk factor for illness temporally associated with yellow fever vaccination. Emerg Infect Dis 2001; 7: 945-51.
195. Chan RC, Penney DJ, Little D, Carter IW, Roberts JA, Rawlinson WD. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet 2001; 358: 121-2.
196. Skowronski DM, Strauss B, De Serres G, MacDonald D, Marion SA, Naus M et al. Oculo-respiratory syndrome: a new influenza vaccine-associated adverse event? Clin Infect Dis 2003; 36: 705-13.
197. Carson JL, Strom BL, Maislin G. Screening for unknown effects of newly marketed drugs. In: Stom BL, ed., Pharmacoepidemiology, 2nd edn. Chichester: John Wiley & Sons, 1994; pp. 431-47.
198. Walker AM. Pattern recognition in health insurance claims databases. Pharmacoepidemiol Drug Saf 2001; 10: 393-7.
199. Ball R. Methods for ensuring vaccine safety. Expert Rev Vaccines 2002; 1: 161-8.
200. Zhou W, Pool V, DeStefano F, Iskander JK, Haber P, Chen RT. A potential signal of Bell's palsy after parenteral inactivated influenza vaccines: reports to the Vaccine Adverse Event Reporting System (VAERS) US 1991-2001. Pharmacoepidemiol Drug Saf 2004; 13: 505-510.
201. Haber P, Iskander J, English-Bullard R. Use of proportional reporting rate ratio in monitoring vaccine adverse event reports. Pharmacoepidemiol Drug Saf 2002; 11: S229.
202. Pool V, Chen RT. Association rule discovery as a signal generation tool for the Vaccine Adverse Event Reporting System. Pharmacoepidemiol Drug Saf 2003; 11: S57.
203. Niu MT, Erwin DE, Braun MM. Data mining in the US Vaccine Adverse Event Reporting System (VAERS): early detection of intussusception and other events after rotavirus vaccination. Vaccine 2001; 19: 4627-34.
204. Banks D, Woo EJ, Burwen D, Perucci P, Braun MM, Ball R. Comparison of 4 data mining methods in the US Vaccine Adverse Event Reporting System (VAERS). Pharmacoepidemiol Drug Saf 2003; 12: S138.
205. Rosenthal S, Chen R, Hadler S. The safety of acellular pertussis vaccine vs whole-cell pertussis vaccine. A postmarketing assessment. Arch Pediatr Adolesc Med 1996; 150: 457-60.
206. Finney DJ. The design and logic of a monitor of drug use. J Chronic Dis 1965; 18: 77-98.
207. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001; 10: 483-6.
208. van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 2002; 11: 3-10.
209. Davis RL, Kolczak M, Lewis E, Nordin J, Goodman M, Shay DK, Platt R, Black S, Shinefield H, Chen RT. Active surveillance of vaccine safety: a system to detect early signs of adverse events. Epidemiology 2005; 16: 336-41.
210. Uhari M, Rantala H, Niemela M. Cluster of childhood Guillain-Barre cases after an oral poliovaccine campaign. Lancet 1989; 2: 440-1.
211. Berg SW, Mitchell BS, Hanson RK, Olafson RP, Williams RP, Tueller JE et al. Systemic reactions in U.S. Marine Corps personnel who received Japanese encephalitis vaccine. Clin Infect Dis 1997; 24: 265-6.
212. Kilroy AW, Schaffner W, Fleet WF Jr, Lefkowitz LB Jr, Karzon DT, Fenichel GM. Two syndromes following rubella immunization. Clinical observations and epidemiological studies. JAMA 1970; 214: 2287-92.
213. Yergeau A, Alain L, Pless R, Robert Y. Adverse events temporally associated with meningococcal vaccines. Can Med Assoc J 1996; 1154: 503-7.
214. Rantala H, Cherry JD, Shields WD, Uhari M. Epidemiology of Guillain-Barre syndrome in children: relationship of oral polio vaccine administration to occurrence. J Pediatr 1994; 124: 220-3.
215. Braun MM, Ellenberg SS. Descriptive epidemiology of adverse events after immunization: reports to the Vaccine Adverse Event Reporting System (VAERS), 1991-1994. J Pediatr 1997; 131: 529-35.
216. Singleton JA, Lloyd JC, Mootrey GT, Salive ME, Chen RT. An overview of the vaccine adverse event reporting system (VAERS) as a surveillance system. VAERS Working Group. Vaccine 1999; 17: 2908-17.
217. Varricchio F, Iskander J, DeStefano F, Pless R, Braun MM, Chen RT. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J 2004; 23: 287-94.
218. Beeler J, Varricchio F, Wise R. Thrombocytopenia after immunization with measles vaccines: review of the vaccine adverse events reporting system (1990 to 1994). Pediatr Infect Dis J 1996; 15: 88-90.
219. Pool V, Braun MM, Kelso JM, Mootrey G, Chen RT, Yunginger JW et al. US Vaccine Adverse Event Reporting System. Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps-rubella vaccine in the United States. Pediatrics 2002; 110: e71.
220. Braun MM, Patriarca PA, Ellenberg SS. Syncope after immunization. Arch Pediatr Adolesc Med 1997; 151: 255-9.
221. Haber P, Chen RT, Zanardi LR, Mootrey GT, English R, Braun MM. An analysis of rotavirus vaccine reports to the Vaccine Adverse Event Reporting System: more than intussusception alone? Pediatrics 2004; 113: e353-9.
222. Wise RP, Salive ME, Braun MM, Mootrey GT, Seward JF, Rider LG et al. Postlicensure safety surveillance for varicella vaccine. JAMA 2000; 284: 1271-9.
223. Rastogi SC, Wise RP. Exploring associations between vaccine lot potencies and human safety experience. Pharmacoepidemiol Drug Saf 1996; 5: S75.
224. Ellenberg SS, Chen RT. The complicated task of monitoring vaccine safety. Public Health Rep 1997; 112: 10-20.
225. Dayan G, Iskander JK, English-Bullard R, Glasser J, Chen RT. Tracking the lifecycle of vaccines and vaccine lots via the Vaccine Adverse Event Reporting System (VAERS). Pharmacoepidemiol Drug Saf 2002; 11(suppl 1): S117.
226. Verstraeten T, Baughman AL, Cadwell B, Zanardi L, Haber P, Chen RT. Enhancing vaccine safety surveillance: a capture-recapture analysis of intussusception after rotavirus vaccination. Am J Epidemiol 2001; 154: 1006-12.
227. Rosenthal S, Chen R. The reporting sensitivities of two passive surveillance systems for vaccine adverse events. Am J Public Health 1995; 85: 1706-9.
228. Lloyd JC, Chen RT. The Urabe mumps vaccine: lessons in adverse event surveillance and response. Pharmacoepidemiol Drug Saf 1996; 5: S45.
229. Niu MT, Rhodes P, Salive M, Lively T, Davis DM, Black S et al. Comparative safety of two recombinant hepatitis B vaccines in children: data from the Vaccine Adverse Event Reporting System (VAERS) and Vaccine Safety Datalink (VSD). J Clin Epidemiol 1998; 51: 503-10.
230. Food and Drug Administration. Postmarketing expedited adverse experience reporting for human drug and licensed biological products; increased frequency reports. Fed Reg 1997; 62: 34166-8.
231. Begg NT, Gill ON, White JM. COVER (cover of vaccination evaluated rapidly): description of the England and Wales scheme. Public Health 1989; 103: 81-9.
232. Freeman VA, DeFriese GH. The challenge and potential of childhood immunization registries. Annu Rev Public Health 2003; 24: 227-46.
233. Chen RT, Orenstein WA. Epidemiologic methods in immunization programs. Epidemiol Rev 1996; 18: 99-117.
234. Patriarca PA, Laender F, Palmeira G, Oliveira MJ, Lima FJ, Dantes MC et al. Randomised trial of alternative formulations of oral poliovaccine in Brazil. Lancet 1988; 1: 429-33.
235. Bhargava I, Chhaparwal BC, Phadke MA, Irani SF, Chakladhar BK, Maheshwari CP. Reactogenecity of indigenously produced measles vaccine. Indian Pediatr 1996; 33: 827-31.
236. Orenstein WA, Markowitz L, Preblud SR, Hinman AR, Tomasi A, Bart KJ. Appropriate age for measles vaccination in the United States. Dev Biol Stand 1986; 65: 13-21.
237. Booy R, Taylor SA, Dobson SR, Isaacs D, Sleight G, Aitken S et al. Immunogenicity and safety of PRP-T conjugate vaccine given according to the British accelerated immunisation schedule. Arch Dis Child 1992; 67: 475-8.
238. Deforest A, Long SS, Lischner HW, Girone JA, Clark JL, Srinivasan R et al. Simultaneous administration of measles-mumps-rubella vaccine with booster doses of diphtheria-tetanus-pertussis and poliovirus vaccines. Pediatrics 1988; 81: 237-46.
239. Scheifele D, Law B, Mitchell L, Ochnio J. Study of booster doses of two Haemophilus influenzae type b conjugate vaccines including their interchangeability. Vaccine 1996; 14: 1399-1406.
240. Garenne M, Leroy O, Beau JP, Sene I. Child mortality after high-titre measles vaccines: prospective study in Senegal. Lancet 1991; 338: 903-7.
241. Aaby P, Samb B, Simondon F, Knudsen K, Seck AM, Bennett J et al. A comparison of vaccine efficacy and mortality during routine use of high-titre Edmonston-Zagreb and Schwarz standard measles vaccines in rural Senegal. Trans R Soc Trop Med Hyg 1996; 90: 326-30.
242. Expanded programme on immunization (EPI). Safety of high titer measles vaccines. Wkly Epidemiol Rec 1992; 67: 357-61.
243. Black SB, Shinefield HR. b-CAPSA I Haemophilus influenzae, type b, capsular polysaccharide vaccine safety. Pediatrics 1987; 79: 321-5.
244. Meekison W, Hutcheon M, Guasparini R. Post-marketing surveillance of adverse events following PROHIBIT vaccine in British Columbia. Can Dis Wkly Rep 1989; 15: 143-5.
245. Vadheim CM, Greenberg DP, Marcy SM, Froeschle J, Ward JI. Safety evaluation of PRP-D Haemophilus influenzae type b conjugate vaccine in children immunized at 18 months of age and older: follow-up study of 30000 children. Pediatr Infect Dis J 1990; 9: 555-61.
246. Centers for Disease Control and Prevention. Unintentional administration of varicella virus vaccine-United States, 1996. MMWR Morb Mort Wkly Rep 1996; 45: 1017-18.
247. Black S, Shinefield H, Ray P, Lewis E, Hansen J, Schwalbe J et al. Postmarketing evaluation of the safety and effectiveness of varicella vaccine. Pediatr Infect Dis J 1999; 18: 1041-6.
248. Centers for Disease Control and Prevention. Inactivated Japanese encephalitis virus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mort Wkly Rep 1993; 42: 1-15.
249. Liu ZL, Hennessy S, Strom BL, Tsai TF, Wan CM, Tang SC et al. Short-term safety of live attenuated Japanese encephalitis vaccine (SA14-14-2): results of a randomized trial with 26,239 subjects. J Infect Dis 1997; 176: 1366-9.
250. Heijbel H, Chen RT, Dahlquist G. Cumulative incidence of childhood-onset IDDM is unaffected by pertussis immunization. Diabetes Care 1997; 20: 173-5.
251. Solberg LK. DTP Vaccination, Visit to Child Health Center and Sudden Infant Death Syndrome (SIDS): Evaluation of DTP Vaccination. Report to the Oslo Health Council 1985. Besthesda, MD: NIH Library Translation, 1985; pp. 85-152.
252. Bouvier-Colle MH, Flahaut A, Messiah A, Jougla E, Hatton F. Sudden infant death and immunization: an extensive epidemiological approach to the problem in France-winter 1986. Int J Epidemiol 1989; 18: 121-6.
253. Mitchell EA, Stewart AW, Clements M. Immunisation and the sudden infant death syndrome. New Zealand Cot Death Study Group. Arch Dis Child 1995; 73: 498-501.
254. Gale JL, Thapa PB, Wassilak SG, Bobo JK, Mendelman PM, Foy HM. Risk of serious acute neurological illness after immunization with diphtheria-tetanus-pertussis vaccine. A population-based case-control study. JAMA 1994; 271: 37-41.
255. Fullerton KE, Reef SE. Commentary: Ongoing debate over the safety of the different mumps vaccine strains impacts mumps disease control. Int J Epidemiol 2002; 31: 983.
256. Simon PA, Chen RT, Elliott JA, Schwartz B. Outbreak of pyogenic abscesses after diphtheria and tetanus toxoids and pertussis vaccination. Pediatr Infect Dis J 1993; 12: 368-71.
257. Walker AM, Jick H, Perera DR, Thompson RS, Knauss TA. Diphtheria-tetanus-pertussis immunization and sudden infant death syndrome. Am J Public Health 1987; 77: 945-51.
258. Griffin MR, Ray WA, Livengood JR, Schaffner W. Risk of sudden infant death syndrome after immunization with the diphtheria-tetanus-pertussis vaccine. N Engl J Med 1988; 319: 618-23.
259. DeStefano F. The Vaccine Safety Datalink project. Pharmacoepidemiol Drug Saf 2001; 10: 403-6.
260. Verstraeten T, DeStefano F, Chen RT, Miller E. Vaccine safety surveillance using large linked databases: opportunities, hazards and proposed precautionary measures. Expert Rev Vaccines. 2003; 2: 21-9.
261. Ray P, Black S, Shinefield H, Dillon A, Schwalbe J, Holmes S et al. Risk of chronic arthropathy among women after rubella vaccination. Vaccine Safety Datalink Team. JAMA 1997; 278: 551-6.
262. Davis RL, Marcuse E, Black S, Shinefield H, Givens B, Schwalbe J et al. MMR2 immunization at 4 to 5 years and 10 to 12 years of age: a comparison of adverse clinical events after immunization in the Vaccine Safety Datalink project. The Vaccine Safety Datalink Team. Pediatrics 1997; 100: 767-71.
263. Williams JC, ed., Combined Vaccines and Simultaneous Administration: Current Issues and Perspective. New York, NY: Academy of Sciences, 1995.
264. Hinman AR, Rodewald LE, Orenstein WA. Immunizations in the United States. In: Plotkin SA, Orenstein WA, eds, Vaccines, 4th edn. Philadelphia, PA: W.B. Saunders, 2003; pp. 1357-86.
265. Niu MT, Salive ME, Ellenberg SS. Neonatal deaths after hepatitis B vaccine: the vaccine adverse event reporting system, 1991-1998. Arch Pediatr Adolesc Med 1999; 153: 1279-82.
266. Griffin MR, Ray WA, Mortimer EA, Fenichel GM, Schaffner W. Risk of seizures and encephalopathy after immunization with the diphtheria-tetanus-pertussis vaccine. JAMA 1990; 263: 1641-5.
267. Rothman KJ. Causal Inference. Chestnut Hill, MA: Epidemiology Resources, 1988.
268. Andrews N, Miller E, Waight P, Farrington P, Crowcroft N, Stowe J et al. Does oral polio vaccine cause intussusception in infants? Evidence from a sequence of three self-controlled cases series studies in the United Kingdom. Eur J Epidemiol 2001; 17: 701-6.
269. Kaye JA, Mar Melero-Montes M, Jick H. Mumps, measles, and rubella vaccine and the incidence of autism recorded by general practitioners: a time trend analysis. BMJ 2001; 322: 460-3.
270. Roberts JD, Roos LL, Poffenroth LA, Hassard TH, Bebchuk JD, Carter AO et al. Surveillance of vaccine-related adverse events in the first year of life: a Manitoba cohort study. J Clin Epidemiol 1996; 49: 51-8.
271. Ali M, Canh DG, Clemens JD, Park JK, von Seidlein L, Thiem VD et al. The vaccine data link in Nha Trang, Vietnam: a progress report on the implementation of a database to detect adverse events related to vaccinations. Vaccine 2003; 21: 1681-6.
272. Griffin MR, Ray WA, Fought RL, Foster MA, Hays A, Schaffner W. Monitoring the safety of childhood immunizations: methods of linking and augmenting computerized data bases for epidemiologic studies. Am J Prev Med 1988; 4 (suppl 2): 5-13.
273. Mullooly J, Drew L, DeStefano F, Chen R, Okoro K, Swint E et al. Quality of HMO vaccination databases used to monitor childhood vaccine safety. Vaccine Safety DataLink Team. Am J Epidemiol 1999; 149: 186-94.
274. Wilton R, Pennisi A. Evaluating the accuracy of transcribed computer-stored immunization data. Pediatrics 1994; 94: 902-6.
275. Boulianne N, Hemon YA, Mawhinney T, Strong D, Gemmill I, Dobson S et al. National eligible, due, and overdue guidelines for immunization registries: draft recommendations from the Canadian Immunization Registry Network, Data Standards Task Group. Can Commun Dis Rep 2004; 30: 53-9.
276. Hull BP, Lawrence GL, MacIntyre CR, McIntyre PB. Immunisation coverage in Australia corrected for underreporting to the Australian Childhood Immunisation Register. Aust N Z J Public Health 2003; 27: 533-8.
277. McMahon BJ, Helminiak C, Wainwright RB, Bulkow L, Trimble BA, Wainwright K. Frequency of adverse reactions to hepatitis B vaccine in 43,618 persons. Am J Med 1992; 92: 254-6.
278. Street RL Jr. Information-giving in medical consultations: the influence of patients' communicative styles and personal characteristics. Soc Sci Med 1991; 32: 541-8.
279. Walker AM, Jick H, Perera DR, Knauss TA, Thompson RS. Neurologic events following diphtheria-tetanus-pertussis immunization. Pediatrics 1988; 81: 345-9.
280. DeStefano F, Verstraeten T, Jackson LA, Okoro CA, Benson P, Black SB et al. Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch Neurol 2003; 60: 504-9.
281. Ascherio A, Zhang SM, Hernan MA, Olek MJ, Coplan PM, Brodovicz K et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 2001; 344: 327-32.
282. Poser CM. Neurological complications of swine influenza vaccination. Acta Neurol Scand 1982; 66: 413-31.
283. Hotopf M, David A, Hull L, Ismail K, Unwin C, Wessely S. Role of vaccinations as risk factors for ill health in veterans of the Gulf war: cross sectional study. BMJ 2000; 320: 1363-7.
284. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 1991; 133: 144-53.
285. Confavreux C, Suissa S, Saddier P, Bourdes V, Vukusic S. Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. N Engl J Med 2001; 344: 319-26.
286. Farrington CP, Nash J, Miller E. Case series analysis of adverse reactions to vaccines: a comparative evaluation. Am J Epidemiol 1996; 143: 1165-73.
287. Strom BL, Carson JL. Use of automated databases for pharmacoepidemiology research. Epidemiol Rev 1990; 12: 87-107.
288. Gargiullo PM, Kramarz P, DeStefano F, Chen RT. Principles of epidemiological research on drug effects. Lancet 1999; 353: 501.
289. Poland GA, Murray D, Bonilla-Guerrero R. New vaccine development. BMJ 2002; 324: 1315-19.
290. Russo S, Turin L, Zanella A, Ponti W, Poli G. What's going on in vaccine technology? Med Res Rev 1997; 17: 277-301.
291. Ward BJ. Vaccine adverse events in the new millennium: is there reason for concern? Bull World Health Organ 2000; 78: 205-15.
292. Freed GL, Katz SL, Clark SJ. Safety of vaccinations. Miss America, the media, and public health. JAMA 1996; 276: 1869-72.
293. Chen RT, DeStefano F, Davis RL, Jackson LA, Thompson RS, Mullooly JP et al. The Vaccine Safety Datalink: immunization research in health maintenance organizations in the USA. Bull World Health Organ 2000; 78: 186-94.
294. Pless R, Casey CG, Chen RT. Improving the evaluation, management and understanding of adverse events possibly related to immunizations. Available at: http://www.partnersforimmunization.org/cisa.pdf. Accessed: April 1, 2004.
295. Zanoni G, Nguyen TM, Valsecchi M, Gallo G, Tridente G. Prevention and monitoring of adverse events following immunization: the "Green Channel" of the Veneto region in Italy. Vaccine 2003; 22: 194-201.
296. WHO Vaccine Safety Advisory Committee. Vaccine safety. Wkly Epidemiol Rec 1999; 74: 337-40.
297. Weldon D. Before The Institute of Medicine, February 9, 2004. Available at: http://www.iom.edu/includes/DBFile.asp?id=19029. Accessed: April 1, 2004.
298. Murch SH, Anthony A, Casson DH, Malik M, Berelowitz M, Dhillon AP et al. Retraction of an interpretation. Lancet 2004; 363: 750.
299. Horton R. The lessons of MMR. Lancet 2004; 363: 747-9.
300. Horton R. A statement by the editors of The Lancet. Lancet 2004; 363: 820-1.
301. Rock A. Toxic tipping point. Mother Jones 2004; March/April: 70-7.
302. Gellin BG, Maibach EW, Marcuse EK. Do parents understand immunizations? A national telephone survey. Pediatrics 2000; 106: 1097-102.
303. Slovic P. The risk game. J Haz Materials 2001; 86: 17-24.
304. Salmon DA, Moulton LH, Halsey NA. Enhancing public confidence in vaccines through independent oversight of postlicensure vaccine safety. Am J Public Health 2004; 94: 947-50.
305. National Transportation Safety Board. We Are All Safer: NTSB-Inspired Improvements in Transportation Safety. Washington, DC: NTSB, 1998.
306. Wood AJ, Stein CM, Woosley R. Making medicines safer-the need for an independent drug safety board. N Engl J Med 1998; 339: 1851-4.
307. Committee on Quality of Health Care in America. Kohn LT, Corrigan JM, Donaldson MS, eds, To Err Is Human: Building a Safer Health System. Washington, DC: National Academy Press, 2000.
308. Pless RP, Bentsi-Enchill AD, Duclos P. Monitoring vaccine safety during measles mass immunization campaigns: clinical and programmatic issues. J Infect Dis 2003; 187(suppl 1): S291-8.
309. Pope J, Stevens A, Howson W, Bell D. The development of rheumatoid arthritis after recombinant hepatitis B vaccination. J Rheumatol 1998; 25: 1687-93.
310. Khoury MJ. Genetics and genomics in practice: the continuum from genetic disease to genetic information in health and disease. Genet Med 2003; 5: 261-8.